Fate Therapeutics Inc (FATE)

[jondoeuk]

Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1327

Long-Term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-Shelf Immunotherapies https://annualmeeting.asgct.org/abstracts/testing/abstract-details?abstractId=1326

Generation of Human Myeloid Derived Suppressor Cells from Induced Pluripotent Stem Cells (IPSC) for Graft versus Host Disease Therapy https://annualmeeting.asgct.org/abstracts/testing/abstract-details?abstractId=1669

Long-Term Stability Assessment of IPSC-Derived T and NK Cells Support the Feasibility of Off-the-Shelf Therapeutic Applications https://annualmeeting.asgct.org/abstracts/testing/abstract-details?abstractId=1655

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody Represent a Novel Therapeutic Strategy to Avoid Host Immune Cell Rejection for Off-the-Shelf Cell-Based Cancer Immunotherapy https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1603

10-Year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1323

Robust T-Cell Cellular Reprogramming and Single-Cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T Cells https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1325

Development of Next-Generation, Off-the-Shelf CAR T-Cell Immunotherapies for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1272

FT536: A First-of-Kind, Off-the-Shelf CAR-iNK Cell Product Candidate for Solid Tumors Designed to Specifically Target MICA/B Stress Proteins and Overcome Mechanisms of Tumor Evasion https://annualmeeting.asgct.org/abstracts/testing/abstract-details?abstractId=1765